Disitamab vedotin binds HER2, is internalized, and releases MMAE that binds the vinca site on beta‑tubulin to disrupt microtubules, causing G2/M arrest and apoptosis in HER2+ cells (with possible Fc-mediated ADCC). Beta‑tubulin expression alone does not confer susceptibility.